Corbus Pharmaceuticals Holdings Inc
Change company Symbol lookup
Select an option...
CRBP Corbus Pharmaceuticals Holdings Inc
PTI Proteostasis Therapeutics Inc
CALB California BanCorp
$NOPM2 Refinitiv Norway Metal & Mining Inde
EBAY eBay Inc
PTON Peloton Interactive Inc
GO Grocery Outlet Holding Corp
NUE Nucor Corp
SJM J M Smucker Co
KR Kroger Co
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

Corbus Pharmaceuticals Holdings, Inc. is a Phase-III, clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and halt fibrotic processes. Lenabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing lenabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).

Postmarket

Last Trade
Delayed
$1.20
-0.02 (-1.64%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$1.22
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
1.26
Day's Low
1.18
Volume
(Light)
Volume:
3,095,769

10-day average volume:
4,789,899
3,095,769

STAA DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds STAAR Surgical Company of Class Action and Encourages Shareholders to Contact the Firm

11:00 am ET October 14, 2020 (Newsfile) Print

New York, New York--(Newsfile Corp. - October 14, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against STAAR Surgical Company("STAAR" or the "Company") (NASDAQ: STAA) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired STAAR securities between February 26, 2020 through August 10, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/staa.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, Defendants made materially false and misleading and/or failed to disclose that material adverse facts. Specifically the complaint alleges that defendants were overstating and/or mischaracterizing: (1) its sales and growth in China; (2) its marketing spend; (3) its research and development expenses; and that as a result of the foregoing, (4) Defendants' public statements were materially false and misleading at all relevant times.

On August 11, 2020, research firm J Capital published a report that called into question STAAR's representations with respect to its purported success in the Chinese market, accusing the Company of overstating its sales in China by at least one-third (or $21.6 million). Citing over 75 interviews with former employees, site visits to China and Switzerland, and an extensive review of public documents, the J Capital report asserted that STAAR has reported fake sales revenues by overstating sales and then marking up actual marketing costs to hide "phantom" revenue. On this news, STAAR's stock price fell $3.17 per share, or 6.16%, to close at $48.25 per share on August 11, 2020.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/staa or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in STAAR you have until October 19, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/65707

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.